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Abstract In clinical toxicology, fast and specific methods
are necessary for the screening of different classes of drugs.
Therefore, an online extraction high-performance liquid
chromatography coupled to mass spectrometry (LC-MSn)
screening method using a MS2 and MS3 spectral library for
the identification of xenobiotic substances has been
developed and validated. Samples were run twice, once
native and once after enzymatic hydrolysis. Internal
standards and buffer were added to the urine samples.
Following centrifugation, the supernatant was injected into
the system. Extraction was performed by online turbulent
flow chromatography. The chromatographic separation was
achieved using a Phenyl/Hexyl column. For detection, a
linear ion trap, equipped with an APCI interface, was used
and the different compounds were identified using a MS2
and MS3 spectral library containing 356 compounds. The
turnaround time to report the results of the screening
including hydrolysis was approximately 2 h. About 92% of
the 356 substances could be identified with a limit of
identification below 100 ng/ml. The recovery and matrix
effect experiments showed suitable results, and in six drug-
free urine samples of healthy volunteers analyzed for
selectivity, no substances have been identified. Carryover
could be well controlled, and the method had a good
reproducibility. The comparison of the results of 103 real
patient urine samples showed a good agreement between
the existing GC-MS and LC-MS methods with offline
extraction and the new online extraction LC-MSn screening
method. The presented method allows a fast and sensitive
analysis of a broad range of compounds.
Keywords LC-MS . Turbulent flow chromatography .
Online extraction . Toxicological screening . Clinical
toxicology
Introduction
The most often used techniques for toxicological screening
purposes are immunological screening systems and gas
chromatography-mass spectrometry (GC-MS) methods [1].
Immunological screening systems are fast, but often show
cross-reactivities with other substances, e.g., metabolites or
other drugs which can lead to false-positive results [2].
Moreover, immunological screening methods are only
available for a limited number of compounds.
GC-MS nowadays is used as gold standard in the
clinical-toxicological laboratory. Several large libraries
including 100,000s of substances are commercially avail-
able [3] which makes this approach very powerful for the
identification of unknown substances. However, not all
substances potentially involved in intoxications can be
analyzed using GC-MS. For example, the analysis of
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thermolabile substances and compounds with a high
molecular weight is impossible using this technique.
Moreover, GC-MS needs extensive, mostly manual sample
preparation that slows down the process and can be an
origin of errors.
In the field of liquid chromatography screening, diode
array detectors (DAD) were the most popular detectors used
for a long time. Like in GC-MS, a standardization of the
ultraviolet/visible (UV/VIS) spectra was possible [4]
leading to the development of large commercially available
libraries. The major drawbacks of this method are in some
cases the bad specificity of the generated UV/VIS spectra
and the poor UV/VIS activity of some compounds [4].
High-performance liquid chromatography (HPLC)/DAD
systems can also be used in combination with online
extraction [5]. One important approach to mention here is
the REMEDi system [6] that was commercially available
and widely used in clinical and forensic toxicological
laboratories but which is no longer available.
Several screening methods have been developed using
HPLC coupled to mass spectrometry (LC-MS). MS/MS or
MSn spectra can be used for the identification of sub-
stances, either generated on single-stage quadrupole instru-
ments (via in-source collision) [7, 8], ion trap instruments
[9–11] or hybrid instruments [12–14]. A comparison of
three different commercially available screening systems
using either a single-stage quadrupole, an ion trap or a triple
quadrupole–ion trap hybrid instrument with GC-MS and
the REMEDi system has been published recently [15].
Some larger LC-MS spectral libraries have already been
published [16]. The main issue with LC-MS/MS or LC-
MSn spectra is the poor reproducibility of the spectra
obtained from different types of mass spectrometers [17],
even though some progress has been made recently in this
area [18–20].
In targeted screening approaches using a triple quadru-
pole instrument, the monitoring of different multiple
reaction monitoring (MRM) transitions can be used to
detect substances [21].
As alternative to full-scan spectra, it is now possible to
identify compounds using their exact masses. Several
methods using offline extraction and a time-of-flight mass
spectrometer [22, 23] or a quadrupole–time-of-flight hybrid
instrument [24] have been published recently.
Online extraction using turbulent flow chromatography
has been used for the analysis of different substances and
for various matrices, e.g., immunosuppressants in whole
blood [25] or antidepressants in serum [26]. This extraction
method works with large, porous stationary particles, where
small molecules can diffuse into, whereas matrix constitu-
ents, e.g., proteins, are washed to the waste with the dwell
volume of the column. To our knowledge, this method has
not been used so far for the extraction of several hundreds
of substances as it is required in case of a toxicological
screening approach.
In this paper, we present a fast and sensitive screening
method using turbulent flow chromatography for sample
preparation, thereby omitting extensive manual sample
preparation steps.
Materials and methods
Chemicals and reagents
HPLC grade ammonium acetate and ammonium carbonate
were purchased from Scharlau (Taegerig, Switzerland), and
analytical grade formic acid and ammonia were from Merck
(Darmstadt, Germany). HPLC gradient grade methanol and
2-propanol was purchased from Seelze GmbH (Seelze,
Germany), acetonitrile from Romil (Cambridge, Great
Britain), acetone from Merck (Darmstadt, Germany), and
dimethylsulfoxide from Fluka (Buchs, Switzerland). Puri-
fied water was obtained using a central water purification
installation (Burkhalter AG, Worblaufen, Switzerland). The
356 reference compounds which have been used to build
the MS2 and MS3 library have been obtained as reference
compounds by commercial suppliers (e.g., Cerillant (Round
Rock, TX, USA), Lipomed (Arlesheim, Switzerland)) or by
the manufacturers of the marketed drug.
LC-MS analysis
Equipment
The HPLC system consisted of a Transcend TLX-1 HTLC
system, equipped with two Allegro pumps, an HTC PAL
autosampler, and a valve interface module with built-in
switching valves, all controlled by the Aria software
(version 1.6.2). The MS analysis was performed using a
LXQ linear ion trap mass spectrometer, controlled by the
Xcalibur 2.0.7 SP1 software (all from Thermo Fisher
Scientific, Basel, Switzerland). Due to its better perfor-
mance in terms of matrix effects compared with electro-
spray ionization [27], an atmospheric pressure chemical
ionization (APCI) interface was used.
Spectral library and identification of compounds
Reference spectra have been acquired in-house by direct
infusion of a solution containing the reference compounds
at a concentration of 10,000 ng/ml into the MS. ToxID
2.1.1 (Thermo Fisher Scientific, Basel, Switzerland) was
used for the automated processing of chromatograms and
the creation of the report. The library algorithm of ToxID
compared all spectra acquired during the chromatographic
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run with the ones from the library and reported the hits,
where the search fit and reverse search fit as well as the
retention time were within the range specified in the
processing method. The minimal search fit was set to 600;
the minimal reverse search fit was set to 700. The tolerance
for the retention time was set to 1.5 min. Retention time
shifts above 1.5 min would have to be considered manually
and would not be corrected automatically by ToxID using
the retention time of the internal standards. Compounds
were identified using both MS2 and MS3 reference spectra
from the spectral library as well as retention times, which
have been determined by injecting spiked urine samples
into the system.
Sample pre-treatment
Samples were run both natively and hydrolyzed. For the
native aliquot, 100 μl of sample were diluted with 50 μl of
ammonium acetate buffer 50 mM (pH 4) and 10 μl of
methanolic internal standard solution containing 10,000 ng/
ml of each temazepam-d5, haloperidol-d4, and morphine-
d3 were added. The three internal standards were chosen in
order to get a reference for the retention times over the
whole chromatographic run and to control the efficiency of
both extraction columns. The samples were vigorously
vortexed and centrifuged for 5 min at 11,700×g and 10 °C.
130 μl of the supernatant were transferred into an
autosampler vial.
The procedure for the hydrolysis was adapted from
Eichhorst et al. [21]. 500 μl of urine were acidified
with 10 μl of glacial acetic acid, and 50 μl of beta-
glucuronidase/arylsulfatase from Helix pomatia were
added. After vortexing, the samples were placed in a water
bath (55 °C) for 1 h. An aliquot of 200 μl of the hydrolyzed
sample was diluted with 100 μl ammonium acetate buffer
50 mM (pH 4) and 20 μl of the abovementioned methanolic
internal standard solution were added. After vigorous
vortexing and centrifugation for 5 min at 11,700×g and
10 °C, 250 μl of the supernatant was transferred into an
autosampler vial.
LC method
100 μl of the sample were injected into the LC system.
Extraction was done using two columns in series, a Cyclone
and C18XL extraction column (Thermo Fisher Scientific,
Basel, Switzerland). A Betasil Phenyl/Hexyl column, 100×
3 mm with 3 μm particle size (Thermo Fisher Scientific,
Basel, Switzerland) was utilized as an analytical column. A
schematic view of the online extraction system with the
different steps can be seen in Fig. 1. The following eluents
were used: loading B, 10 mM ammonium carbonate buffer
in water; loading C, 2-propanol/acetone/acetonitrile 1/1/1
(v/v/v); eluting A, 5 mM ammonium acetate in water +0.1%
formic acid; eluting B, 5 mM ammonium acetate in
methanol +0.5% formic acid; eluting C, 2-propanol/ace-
tone/acetonitrile 1/1/1 (v/v/v). The details of the gradient
applied and the flow rates used are reported in Table 1.
Chromatography was performed at room temperature
(approximately 24 °C), and the LC flow was diverted into
the waste between 0 and 0.8 min and 27 and 32.35 min,
respectively, using a divert valve.
MSTF AC
EP
LP Wastea.) b.)
TF AC
EP
LP Waste
MS
MSTF AC
EP
LP Waste
c.)
Fig. 1 Configuration of the online extraction system. LP loading
pump for the online extraction, EP eluting pump for the analytical
chromatography, TF turbulent flow extraction columns, AC analytical
column, MS mass spectrometer. a Loading, as well as washing, and
equilibration step, corresponds to steps 1–2 and 9–15 in Table 1. b
Short back-flush step, to remove precipitates from the entry frit of the
extraction column to avoid clotting of the analytical column,
corresponds to step 3 in Table 1. c Elution of the analytes from the
extraction column and analytical chromatography, corresponds to
steps 4–8 in Table 1
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MS conditions
The compounds were ionized using an APCI source. The
vaporizer temperature was set to 450 °C, the sheath gas to
30 arbitrary units (AU) and the auxiliary gas to 5 AU. The
discharge current was set at 5 μA, and the capillary
temperature was maintained at 275 °C. Polarity was
switched from positive to negative mode within the same
run. Normalized collision energy of 35% was used for the
generation of full-scan MS2 and MS3 spectra. The
acquisition of the chromatograms was performed using
data-dependent acquisition with polarity switching. A data-
dependent scan was triggered when a precursor mass from a
predefined list was detected with an intensity above 100
counts per second.
In MS1, the mass range used was between 100 and
1,000 amu. The mass ranges for MS2 and MS3 spectra were
automatically set by the instrument when performing data-
dependent acquisition. The upper mass value was set 10 to
15 amu above the mass of the precursor ion and the lower
mass at the low-mass cut-off of the instrument (about one
fourth of the precursor mass). All scans were performed in
full-scan mode.
Established toxicological screening methods
The established toxicological screening methods have been
used for the analyses of patient samples, which have then
been reanalyzed by the new LC-MSn screening method.
The main method used was a GC-MS screening procedure
using 2 ml native urine and 2 ml chemically hydrolyzed
urine. After liquid–liquid extraction, the extract was divided
into two parts and two different derivatization procedures
were applied (silylation and acetylation) [28]. In addition,
targeted LC-MS2 screening methods were performed for
the detection of amphetamines, antidepressants, beta-
blockers, cocaine, dextromethorphan, methadone, opiates,
and zolpidem. The urine samples were extracted using
offline solid-phase extraction, and the chromatographic
conditions as well as the data-dependent MS2 acquisitions
have been optimized for the different groups of compounds
[29].
Method validation
Specificity
Urine samples of six different healthy volunteers who were
not taking any medications were analyzed and searched
against the spectral library.
Matrix effects
Matrix effects were evaluated qualitatively according to the
method described by Bonfiglio et al. [30]. Urine samples
from six different patients who were not taking any
medications were pre-treated as described above. Five out
of the six urine samples were selected to show pathological
values for ketone bodies, urobilinogen, protein, hemoglo-
bin, or bacteria (urine 1—ketone bodies, 800 mg/l and
Table 1 Gradient used
Step no. Time Flow LP (ml/min) Loading B (%) Loading C (%) Flow EP (ml/min) Eluting A (%) Eluting B (%) Eluting C (%)
1 0 2 100 0.3 99 1
2 0:50 2 100 0.3 99 1
3 0:55 0.5 100 0.3 99 1
4 1:35 0.5 100 0.3 99 1
5 7:15 0.01 100 0.3 55 45
6 14:45 0.01 100 0.3 40 60
7 23:05 0.01 100 0.3 2 98
8 25:05 0.01 100 0.5 2 98
9 27:05 2 100 0.5 2 98
10 27:06 2 100 0.5 2 100
11 29:05 2 100 0.5 100
12 29:35 2 100 0.5 100
13 31:35 2 100 0.5 99 1
14 31:36 2 100 0.3 99 1
15 32:35 2 100 0.3 99 1
The total method duration was 32:35 min
LP loading pump for the online extraction, EP eluting pump for the analytical chromatography
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protein, 300 mg/l; urine 2—ketone bodies, 400 mg/l and
protein, 300 mg/l; urine 3—urobilinogen, 40 mg/l; urine
4—protein, 300 mg/l; urine 5—hemoglobin, 10 mg/l and
bacteria (not differentiated or identified), 21/μl of urine;
urine 6—healthy volunteer).
Forty-seven representative substances (Table 2) have
been selected to cover the whole retention time range and
mass range. During the injection of the six urine samples
by the autosampler, the 47 substances (each, 1,000 ng/ml)
were introduced in groups of eight to ten substances by
post-column infusion via a T-valve with a flow rate of
3 μl/min.
The approach for the quantitative evaluation of matrix
effects was adapted to the one described by Matuszewski
et al. [31]. The same urine samples as used in the
qualitative analysis were spiked with the same mixtures of
47 substances at 100 and 1,000 ng/ml to simulate different
concentrations observed in intoxication cases. The resulting
peak areas were compared with the peak areas of neat
standards in solvent (n=6).
Recovery
The recovery was determined at 100 ng/ml (n=6) with the
same 47 substances already used for the matrix effect
experiments. Recovery was calculated by dividing the peak
area of the standards in solvent injected onto the extraction
columns with subsequent analytical chromatography by the
peak area of standards in solvent injected directly onto the
analytical column, omitting the online extraction step. In
analogy to Matuszewski et al. [31], no spiked urine samples
were used to clearly distinguish between matrix effects and
recovery.
Limit of identification
Aliquots of pooled blank urines from different healthy
volunteers not taking any medications were spiked with all
356 substances to achieve a concentration of 10, 100, and
1,000 ng/ml of each substance. The lowest concentration
where a substance was identified by ToxID was considered
as the limit of identification (n=3).
Carryover
Carryover was tested for all 356 substances by injecting urine
samples spiked with 10,000 ng/ml in groups of ten sub-
stances/urine. Two blank samples were injected following the
high concentrated urine and searched against the library to
detect the presence of any substances. The peak heights of the
first blank samples were divided by the peak height of the
highly concentrated standard to get a quantitative evaluation
of carryover.
Reproducibility
For all reproducibility experiments, the same set of
compounds already used for the determination of the matrix
effects and the recovery have been used at a concentration
of 100 ng/ml.
The reproducibility of retention times was checked both
within day (n=6) and between days (n=6) by calculating
the coefficient of variation (CV) of the retention times. The
between-day analysis included columns of different lots to
check its influence.
The reproducibility of the measured mass-to-charge
ratios was checked both within day (n=6) and between
days (n=6) by calculating the CV of the mass-to-charge
ratio of the most intense peak of the MS2 spectra of the
compounds.
The reproducibility of the mass spectra was checked
both within day (n=6) and between days (n=6) by
calculating the CV of the matching factors (search fit)
reported by ToxID.
Analysis of patient samples
A total of 103 patient samples which were already analyzed
by the GC-MS procedure [28], existing targeted LC-MS2
screening methods [29], and immunological screening
methods were reanalyzed with the new online extraction
LC-MSn screening method. The samples have been stored
at −20 °C until analysis (for up to 8 months). The results
were analyzed by a person who had no information about
the results obtained from the existing screening methods.
Results
Method validation
Specificity
In urine samples from persons not smoking nor drinking
beverages containing caffeine, no substances have been
identified. In the samples of healthy volunteers drinking
coffee or energy drinks or smoking, besides caffeine,
nicotine, and cotinine, no other substances have been
identified.
Matrix effects
In the qualitative method, ion suppression was observed
only in urine samples positive for ketone bodies in high
concentrations (>400 mg/l). In all other cases, no matrix
effects could be detected. Ion suppression has been
observed mainly at the beginning of the chromatographic
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Table 2 Reproducibility data for mass-to-charge ratio, spectral reproducibility, and retention time variation (intraday and interday, n=6) as well as
matrix effect and recovery data (n=6)
Substance Reproducibility of the
mass-to-charge ratio
Spectral reproducibility Reproducibility of the
retention time
Matrix effect Recovery
Intraday
CV (%)
Interday
CV (%)
Intraday
CV (%)
Interday
CV (%)
Intraday
CV (%)
Interday
CV (%)
Average
(%)
CV
(%)
Average
(%)
CV
(%)
Amiodarone 0.008 0.004 1.09 1.26 0.23 0.60 100 15.2 100 13.0
Amphetamine 0.044 0.039 0.041 0.53 0.47 1.28 100 4.54 73.8 7.27
Amprenavir 0.010 0.009 0.45 0.041 0.34 1.17 100 11.7 100 2.40
Bisacodyl 0.015 0.016 3.12 2.98 0.36 1.45 100 7.81 100 7.78
Buprenorphine 0.018 0.012 0.24 0.24 0.49 1.74 99.3 7.98 100 11.8
Cilazapril 0.013 0.011 0.052 0.16 0.38 1.70 100 12.9 100 13.2
Citalopram 0.009 0.021 0.23 0.20 0.39 1.61 100 3.21 100 4.68
Clarithromycin 0.007 0.007 0.041 0.052 0.30 1.10 100 6.53 100 10.3
Clonidine 0.034 0.042 5.03 1.84 0.58 1.37 100 5.96 98.2 7.06
Cocaine 0.008 0.021 0.45 0.082 0.36 1.20 100 8.30 100 11.0
Colchizine 0.005 0.016 0.063 0.37 0.57 1.87 100 4.00 100 8.43
Darunavir 0.016 0.034 0.041 0.041 0.34 1.11 100 12.7 100 6.41
Dextrorphan 0.021 0.006 0.41 0.29 0.34 1.14 100 14.9 100 12.8
Diacetylmorphine 0.006 0.013 0.084 0.075 0.31 1.05 100 15.2 100 10.9
Diazepam 0.009 0.013 0.052 0.041 0.32 1.01 100 2.06 100 5.33
Digitoxine 0.002 0.002 0.49 0.041 0.23 0.60 100 8.11 100 12.2
Domperidone 0.019 0.021 1.31 1.77 0.57 1.48 100 12.2 100 12.0
EDDP 0.013 0.016 0.041 0.041 0.48 1.74 100 3.00 96.7 2.61
Ergotamine 0.007 0.008 0.95 0.72 1.21 2.47 100 7.51 100 13.6
Fexofenadine 0.007 0.005 0.041 0.12 0.42 1.47 100 12.6 100 6.89
Flufenamic acid 0.005 0.009 0.42 1.20 0.20 0.62 100 15.5 100 14.7
Glimepiride 0.007 0.010 0.13 0.082 0.33 0.77 83.0 15.2 100 13.8
Haloperidol 0.007 0.006 0.45 0.57 0.53 1.78 100 4.00 100 3.17
Irbesartan 0.009 0.018 0.052 0.045 0.32 1.17 99.4 10.9 100 9.89
Itraconazole 0.004 0.009 0.052 0.16 0.20 0.51 70.8 15.7 100 12.4
Ketoconazole 0.005 0.003 0.041 0.041 0.48 1.49 100 3.23 100 5.19
Levomepromazine 0.020 0.035 1.04 0.53 0.40 1.51 100 7.33 95.9 4.56
Lopinavir 0.004 0.005 0.052 0.052 0.12 0.52 77.9 14.6 100 6.47
Mepivacainde 0.011 0.024 2.44 7.22 1.05 0.90 78.1 11.6 100 15.1
Methylecgonine 0.013 0.024 0.94 0.41 0.31 0.66 100 7.21 100 8.37
Morphine 0.012 0.016 0.084 0.94 1.19 2.54 59.6 9.10 100 14.1
Morphine-3-
glucuronide
0.015 0.012 0.11 0.14 1.07 1.73 100 8.86 100 11.6
Nadolol 0.008 0.007 0.082 0.61 1.54 2.03 100 10.5 100 14.2
Nelfinavir 0.006 0.013 0.90 1.31 0.27 0.94 100 5.62 100 9.56
Nicardipine 0.008 0.010 0.041 1.85 0.38 1.84 100 4.08 100 4.21
Nicotine 0.009 0.025 7.18 5.01 1.65 2.19 100 4.15 100 4.83
Octodrine 0.061 0.070 0.53 1.40 0.51 1.87 100 8.42 100 2.96
Ondansetron 0.017 0.011 1.40 0.41 0.48 1.06 100 14.9 100 14.2
Paracetamol 0.041 0.041 0.91 1.27 0.66 1.29 96.4 6.22 88.4 4.13
Penfluridol 0.004 0.005 0.075 0.052 0.28 0.64 100 13.9 100 3.57
Pindolol 0.019 0.023 0.52 0.58 0.50 0.78 100 15.4 100 9.42
Ritonavir 0.011 0.012 0.14 0.084 0.17 0.58 95.6 11.3 100 14.2
Roxithromycin 0.002 0.005 0.052 0.082 0.19 1.02 97.4 5.26 100 12.6
Sildenafil 0.007 0.009 0.49 0.50 0.60 1.89 100 4.05 100 10.9
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run and was affecting in tendency compounds having a
lower molecular weight.
With the quantitative method, 89% of the compounds
showed no ion suppression (Table 2). Maximum suppres-
sion of the signal led to a reduction of the signal intensity of
40%. Substances which have been suppressed more than
15% were glimepiride, itraconazol, lopinavir, mepivacaine,
and morphine. It has been demonstrated that the signal,
even with the lower concentration tested (100 ng/ml), was
not completely lost and all the compounds could still be
identified by ToxID. Since the method is not intended to be
used as a quantitative method, these results were considered
as acceptable.
Recovery
Recovery was above 74% for all compounds tested
(Table 2). About 97% of the substances showed a recovery
higher than 90%, indicating that this new online extraction
procedure is able to extract different compounds having
different polarities and masses with good recoveries.
Limit of identification
The limit of identification was below 10 ng/ml for 213
(60%) out of the 356 substances which were part of the
library. At a concentration of 100 ng/ml, 329 (90%) of all
compounds could be identified, and at 1,000 ng/ml, all
substances have been successfully identified, which makes
it possible to detect most of the substances in urine already
after the intake of therapeutic doses. The limits of
identification for all 356 compounds tested are reported in
the Electronic supplementary material (Table S1).
Carryover
The carryover for all substances was below 1% for all
substances in the first blank sample after injection of the
highly concentrated spiked urine. In the second blank, no
substances have been identified.
In order to prevent any misleading results due to
carryover, a blank sample was run after the injection of
every patient sample.
Reproducibility
Reproducibility data are shown in Table 2. The CV for the
reproducibility of the retention time was below 1.7% for the
intraday measurements and below 2.5% for the interday
measurements. Therefore, a time window of 1.5 min was
set for the identification of compounds using ToxID.
The CV for the reproducibility of the measurements of
the mass-to-charge ratios was below 0.06% for the intraday
measurements and below 0.07% for the interday measure-
ments, indicating an excellent calibration stability of the
non-high resolution instrument.
The CV for the reproducibility of the mass spectra was
below 7.2% both for the intraday and the interday measure-
ments, demonstrating good reproducibility of the fragmen-
tation pattern.
Analysis of patient samples
An example of a real patient urine sample chromatogram is
shown in Fig. 2.
Among 103 patient samples, a total of 451 substances
could be identified using the combination of both, the
established methods and the new method (Fig. 3). When
using only the established methods, 354 substances (78%,
106 different compounds) could be found. Applying only
the method presented, 404 substances (89%, 100 different
coumpounds) could be identified. For seven patient
samples, no compounds have been detected.
Forty-one substances identified by the established
methods could not be detected with the new screening
method. Out of these compounds, 38 substances (93%)
were at the time when the samples have been analyzed not
yet included in the library. This illustrates clearly the need
for a library containing more entries. The three remaining
substances (flurazepam and two samples with duloxetine)
Table 2 (continued)
Substance Reproducibility of the
mass-to-charge ratio
Spectral reproducibility Reproducibility of the
retention time
Matrix effect Recovery
Intraday
CV (%)
Interday
CV (%)
Intraday
CV (%)
Interday
CV (%)
Intraday
CV (%)
Interday
CV (%)
Average
(%)
CV
(%)
Average
(%)
CV
(%)
Tranylcypromine 0.021 0.030 0.90 0.66 0.67 0.64 98.6 7.47 93.4 14.9
Triazolam 0.008 0.014 0.076 0.15 0.40 1.25 100 6.48 100 8.43
Trimipramine 0.030 0.020 1.26 1.02 0.30 1.48 100 4.86 100 4.58
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were only present at very low concentrations and were
therefore below the limit of identification of the new method.
Eighty-six substances (38 different compounds) have
been newly identified with the online screening method
(Table 3). Out of these 86 substances, 52 (60%) could be
reconfirmed by using dedicated methods (LC-MS/MS
methods in MRM mode or LC-MS2 methods with library
matching). For the remaining 34 newly identified substan-
ces, unfortunately, no confirmatory analysis was possible
since there was not enough sample material left for a
reconfirming analysis or there was no specific confirmatory
method available in our laboratory.
In the four cases where a reconfirmation of the
newly identified midazolam was not possible, alpha-
hydroxymidazolam has also been identified, which con-
firms the presence of midazolam in the sample. The same
behavior was observed with the newly identified trazodone,
where also its main metabolite, mCPP, has been identified
in all cases. When clonazepam was identified by the new
method, its metabolite 7-aminoclonazepam could also be
found.
Discussion
In our laboratory, we often observed a higher matrix effect
using electrospray ionization compared with APCI. This
effect has also been described in the literature [27]. For that
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Fig. 2 Example chromatogram and spectra. a Chromatogram of a real
patient case with identified substances annotated (total ion chromato-
gram). b Acquired MS3 spectrum of a metabolite of the antidepressant
clomipramine, desmethylclomipramine, from the chromatogram
shown in (a). c Library MS3 spectrum of desmethylclomipramine
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reason, we have decided to use APCI as the ionization
mode for the screening method. One issue when using
APCI is the higher likelihood of getting in-source frag-
mentation; therefore, occasionally a fragment of a substance
was used as a precursor ion instead of the molecular ion (cf.
Electronic Supplementary Material (Table S1)).
During the method development, it became obvious that
not all glucuronide metabolites could be retained during
extraction. Whereas, morphine glucuronides could be
detected, glucuronides of benzodiazepines, and beta-
blockers were directly eluted to the waste, if present at
low concentrations. Unfortunately, reference compounds
for these metabolites were not available; therefore, an
estimation of the identification limit was not possible.
Consequently, the enzymatic hydrolysis step was added to
cleave the glucuronides and allow the identification of these
compounds. Out of the 110 different compounds identified
with the new method in the 103 patient samples, 15% could
only be detected after hydrolysis, all belonging to the drug
classes mentioned above.
At the moment, our library contains 65 important
metabolites (18% of all entries). As some substances are
excreted exclusively as metabolites, more metabolites have
to be added in the near future.
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Fig. 3 Results of the analysis of patient samples (n=103). Displayed
is a the total number of identified substances in these urine samples
and b the number of different compounds identified with the
established methods, the new method and the total by combining all
methods
Table 3 Substances which were newly identified using the LC-MSn
online screening method
Substance No. of
reconfirmed
No. where no
reconfirmation
was possible
7-Aminoflunitrazepam 1 1
Alprazolam and alpha-
hydroxyalprazolam
3
Atropine 2 1
Benzoylecgonine 3
Bisoprolol 1
Citalopram 1 1
Clarithromycin 1
Clonazepam and
7-aminoclonazepam
2
Clozapine and
norclozapine
1
Diclofenac 1
Fentanyl 2
Haloperidol and reduced
haloperidol
2
Ketamine 1
Lorazepam 1 1
Metamizol 1
Methadone and EDDP 1
Metoclopramide 4
Midazolam 2
Midazolam and alpha-
hydroxymidazolam
7 4
Morphine 8 1
Naloxone 1
Paracetamol 2 2
Pethidine 2
Pipamperone 2
Promazine 2
Propranolol 3
Quetiapine 1
Ranitidine 1
Risperidone and
9-hydroxyrisperidone
2
Salbutamol 1 1
Sulfamethoxazol 1
Topiramate 1
Trazodone and mCPP 1
Trimethoprim 1
Tropisetron 3 1
Urapidil 1
Vecuronium 1
Zolpidem 1
Zuclopenthixol 1
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Regarding the handling of the samples, the presented
screening method requires only few manual steps due to the
online extraction procedure, thereby reducing the risk for
handling errors and also reducing variability of the results.
Compared to existing GC-MS screening methods, the
presented screening method offers several advantages. First
of all, the new method is faster than the GC-MS screening
method used in our laboratory as the total turnaround time
for the analysis of a urine sample analysis in the case of
intoxication is approximately 2 h (including hydrolysis),
instead of the approximately 4 h required with our GC-MS
procedure. Additionally, the method uses only 600 μl of
sample material which is much less than the 4 ml required
for the GC-MS analysis.
As compared with GC-MS, the most important disad-
vantage of the new method is the limited size of the library.
The classical disadvantage of LC-MS mass spectra as
compared with GC-MS mass spectra is the reduced number
of fragments in the LC-MS mass spectra in most cases. By
using MS3 spectra whenever possible, the number of
fragments could be increased.
Compared with the HPLC/DAD screening methods or
the REMEDi system, full-scan MS2 and MS3 spectra offer a
much better specificity.
Detection with exact mass instruments is a newer trend
in the field of screening with LC-MS. The advantages of
screening with exact mass instruments include the ability to
retrospectively look at the data and thereby be able to
identify new compounds that were not part of the library at
the time the analysis took place. With the presented
approach, the mass of the parent ion not part of the library
can also be retrieved, but there are no MS2 or MS3 spectra
acquired which would enable library searching.
Several years ago, Decastecker et al. [24] presented a
method using a combined quadrupole–time-of-flight instru-
ment with offline solid-phase extraction. Limits of identi-
fication obtained with this method are very close to the one
we have obtained using our screening approach.
Dresen et al. [16] recently published a library with over
1,200 substances on a hybrid triple quadrupole - linear ion
trap instrument, which is a reasonable size for routine usage.
A similar approach was already presented in 2006 by
Sauvage et al. [32]. Offline solid-phase extraction was
chosen as the extraction method. In this paper ion
suppression was also investigated. The authors stated that
with the 20 compounds they checked, no ion suppression
was observed in the retention time range from 5.5 to
18.5 min. However, it is not clear if they also checked urine
samples positive for ketone bodies, since ketone body
positive urine samples are the only samples showing ion
suppression under the setting presented here.
Lee et al. [22] recently published a method using ultra-
performance liquid chromatography (UPLC) coupled to a
time-of-flight mass spectrometer for screening. Extraction
was performed offline using an acidic and an alkaline
fraction. Over 300 substances were included in the library.
The limits of identification were in a similar range as with
the method presented here. Matrix effects were also
checked for a subset of compounds. With a maximal ion
suppression of 50%, the results are comparable with our
findings. However, the authors state that the urine samples
used in these experiments were obtained from healthy
volunteers. Since ketone bodies in urine are a sign of a
metabolic lapse, it is unlikely that the urine samples from
the volunteers were containing ketone bodies. Regarding
the recovery, the authors stated a recovery between 0% and
80% for the substances they checked. With our online
extraction system, recoveries were higher than 74% for all
evaluated compounds.
Eichhorst et al. [21] recently presented a method using
UPLC coupled to a triple stage quadrupole instrument in a
screening approach for the detection of 40 different
compounds. The screening method was intended as
replacement for drug of abuse screening with immuno-
assays, not a broad toxicological screening method.
Detection of the compounds was performed using the ratio
between two MRM transitions scanned for each compound.
In our opinion, full-scan spectra give a much better
specificity, especially when combined with retention time
as orthogonal identification point. Also in this paper, matrix
effects were taken into account. The authors state that the
maximum loss of sensitivity was about 8%, but the origin
of the urine matrices is unclear. Recoveries for the selected
substances ranged between 80% and 118% and are
therefore comparable to the results obtained with our
method.
Two methods were published very recently using also
ion trap instruments very similar to the one used in this
paper. Liu et al. [9] presented a method where the library
contains about 800 compounds. Liquid-liquid and solid-
phase extraction of each 1 ml sample was used for sample
preparation. The limits of identification were comparable
with the method presented here; however no evaluation of
matrix effects or recovery was performed.
Sturm et al. [11] published a method using an online
extraction system based on online solid-phase extraction
and APCI. Acquisition of spectra was performed in a very
similar way as presented in this paper using data-dependent
acquisition. However, the authors used two different runs,
one in positive and one in negative mode, whereas in our
approach, positive and negative scans are combined in a
single run. Matrix effect experiments as well as limits of
identification showed similar results. The size of the library
was almost the same as in this paper with 365 compounds
as compared with 356 compounds. Identification of the
substances was based on the relative retention time as well
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as the MS2 spectra. The method presented here uses
retention times as well as MS2 and MS3 spectra which
brings an additional level of specificity.
Conclusions
To our knowledge, this is the first description of an LC-
MSn screening method for the detection of 356 compounds
using online extraction with turbulent flow chromatogra-
phy. Since polarity switching was used, a single injection of
a sample containing unknown compounds was sufficient to
detect both substances ionizing in negative and positive
modes. The presented method allows a fast and sensitive
analysis of a broad range of compounds.
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